The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. METHODS: The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin. RESULTS: The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79). CONCLUSIONS: A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although HRV testing is largely confined to the research setting, the CV reflex tests that assess changes in HRV during standardized clinical challenges such as deep breathing, Valsalva maneuver and supine-to-standing position remain the gold standard tests and are available for clinical care as well.547,614,626”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [626]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to traditional risk factors, hyperglycemia, hyperinsulinemia, and oxidative stress contribute to endothelial damage, leading to poor arterial function and greater susceptibility to atherogenesis ( 45 , 82 , 289 ).”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, studies in people with T2D and early CKD demonstrated the long-term bene fi t of multifactorial intervention on the development of microvascular and macrovascular complications and mortality.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (222,227,228).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [227]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (211,216,217).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [216]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people who already have diabetes, lifestyle modification and pharmacological treatment, as well as blood pressure and cholesterol control, can delay progression to complications and reduce mortality, or even help with remission, especially if started early.1,2,58–62”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“The benefit of the intensive multifactorial intervention was demonstrated by a significant reduction in the incidence of microvascular complications after 4 years, and a significant 53% risk reduction in macrovascular complications after 8 years.455”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [455]
In the citing paper
“Angiotensin-converting enzyme inhibitors812), angiotensin Ⅱ receptor blockers813), and calcium channel antagonists814) have been reported to be effective for preventing cardiovascular events in patients with DM.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [813]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Research works printed but not linked: 2
- 10.1001/jama.241.19.2035 · DOI · Paper page
- 10.1001/archinte.151.6.1141 · DOI
Cited by
Sorted by citations
Items 801–900 of 1,025
Ajjan, R., & Grant, P. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.023 · Cited by 64
Correa‐Rotter, R., Naicker, S., Katz, I. J., Agarwal, S. K., Valdés, R. H., Kaseje, D. C. O., Rodríguez‐Iturbe, B., Shaheen, F. A. M., & Sitthi‐Amorn, C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09208.x · Cited by 64
RABASA-LHORET, R. P. R., & Chiasson, J. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0612 · Cited by 64
Inpatient to Outpatient Transfer of Diabetes Care: Planning for an Effective Hospital Discharge
Cook, C. B., Seifert, K. M., Hull, B. P., Hovan, M. J., Charles, J. C., Miller-Cage, V., Boyle, M. E., Harris, J. K., Magallanez, J. M., & Littman, S. D. (2009) · Endocrine Practice · doi:10.4158/ep.15.3.263 · Cited by 63
Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Røikjer, J., Mørch, C. D., & Ejskjær, N. (2020) · Current Drug Safety · doi:10.2174/1574886315666200731173113 · Cited by 68
Metabolic Memory for Vascular Disease in Diabetes
Aschner, P. J., & Ruiz, Á. J. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0012 · Cited by 63
Inoue, K., Wada, J., Eguchi, J., Nakatsuka, A., Teshigawara, S., Murakami, K., Ogawa, D., Terami, T., Katayama, A., Tone, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077118 · Cited by 63
Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha)
Bjarnason‐Wehrens, B., Held, K., Hoberg, E., Karoff, M., & Rauch, B. (2007) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-007-0001-0 · Cited by 64
Intensive versus conventional glycaemic control for treating diabetic foot ulcers
Fernando, M. E., Seneviratne, R. M., Tan, Y. M., Lazzarini, P. A., Sangla, K. S., Cunningham, M., Buttner, P. G., & Golledge, J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010764.pub2 · Cited by 67
Hu, H., Hori, A., Nishiura, C., Sasaki, N., Okazaki, H., Nakagawa, T., Honda, T., Yamamoto, S., Tomita, K., Miyamoto, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159071 · Cited by 63
Laxy, M., Knoll, G., Schunk, M. V., Meisinger, C., Huth, C., & Holle, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164704 · Cited by 64
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance
STOLAR, M. W., & CHILTON, R. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80240-0 · Cited by 65
Diabetic nephropathy in the elderly
Blicklé, J. F., Doucet, J., Krummel, T., & Hannedouche, T. P. (2007) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)80056-5 · Cited by 62
Mannucci, E., Monami, M., Dicembrini, I., Piselli, A., & Porta, M. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0069-6 · Cited by 64
Yang, S. N. Y., Burch, M. L., Tannock, L. R., Evanko, S. P., Osman, N., & Little, P. J. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00089.x · Cited by 62
Rabkin, R. (2003) · Clinical cornerstone · doi:10.1016/s1098-3597(03)90014-7 · Cited by 62
Pharmacokinetic Interactions with Thiazolidinediones
Scheen, A. J. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746010-00001 · Cited by 64
Cohen, A., & Horton, E. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182068 · Cited by 62
Treatment of High-Risk Patients with Diabetes
Rachmani, R., Slavacheski, I., Berla, M., Frommer-Shapira, R., & Ravid, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110965 · Cited by 62
ADVANCE Collaborative Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01596.x · Cited by 62
Yu, P. C., Bosnyák, Z., & Ceriello, A. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.12.009 · Cited by 63
Kamiyama, M., Kobayashi, M., Araki, S., Iida, A., Tsunoda, T., Kawai, K., Imanishi, M., Nomura, M., Babazono, T., Iwamoto, Y., et al. (2007) · Human Genetics · doi:10.1007/s00439-007-0414-3 · Cited by 61
Self-citationRefill adherence and polypharmacy among patients with type 2 diabetes in general practice
van Bruggen, R., Gorter, K. J., Stolk, R. P., Zuithoff, N. P. A., Klungel, O. H., & Rutten, G. E. H. M. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1810 · Cited by 61
Bjørgaas, M. R., Vik, J. T., Saeterhaug, A., Langlo, L., Sakshaug, T., Mohus, R. M., & Grill, V. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00464.x · Cited by 61
O’Keefe, J. H., Abuannadi, M., Lavie, C. J., & Bell, D. S. H. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0434 · Cited by 62
Proteinuria and Risk for Stroke and Coronary Heart Disease During 27 Years of Follow-up
Madison, J. R., Spies, C., Schatz, I. J., Masaki, K., Chen, R., Yano, K., & Curb, J. D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.8.884 · Cited by 61
Davison, K. A. K., Negrato, C. A., Cobas, R. A., Matheus, A. S. D. M., Tannus, L. R. M., Palma, C. C. S., Japiassú, L., Carneiro, J. R. I., Rodacki, M., Zajdenverg, L., et al. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-19 · Cited by 65
New therapeutic agents in diabetic nephropathy
Kim, Y., & Park, C. W. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.174 · Cited by 61
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus
Pagidipati, N. J., Návar, A. M., Pieper, K. S., Green, J. B., Bethel, M. A., Armstrong, P. W., Josse, R. G., McGuire, D. K., Lokhnygina, Y. V., Cornel, J. H., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027252 · Cited by 61
Karalliedde, J. J., & Viberti, G. C. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001982 · Cited by 61
Diabetic patients treated with dialysis: complications and quality of life
Sørensen, V. R., Mathiesen, E. R., Watt, T., Bjorner, J. B., Andersen, M., & Feldt‐Rasmussen, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0810-1 · Cited by 61
Ruiz, J. C., Monbaron, D., Parati, G., Perret, S., Haesler, E., Danzeisen, C., & Hayoz, D. (2005) · Hypertension · doi:10.1161/01.hyp.0000169053.14440.7d · Cited by 61
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points
Parving, H., Andersen, S., Jacobsen, P. K., Christensen, P. K., Rossing, K., Hovind, P. H., Rossing, P. R., & Tarnow, L. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2003.11.003 · Cited by 61
Self-citationTang, Y., Shah, H., Bueno Junior, C. R., Sun, X., Mitri, J., Sambataro, M., Sambado, L., Gerstein, H. C., Fonseca, V., Doria, A., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1842 · Cited by 60
A Review on Diabetic Retinopathy
Kour, V., Swain, J., Singh, J., Singh, H., & Kour, H. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998253672231011161400 · Cited by 61
The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease
Kostis, J. B. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6032-4 · Cited by 61
Iwabayashi, M., Taniyama, Y., Sanada, F., Azuma, J., Iekushi, K., Kusunoki, H., Chatterjee, A., Okayama, K., Rakugi, H., & Morishita, R. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.042 · Cited by 60
Diabetic Retinopathy: From Pathogenesis to Treatment
Chakrabarti, S. (2007) · Journal of Diabetes Research · doi:10.1155/2007/69527 · Cited by 60
Preston, R. A., Harvey, P., Herfert, O., Dykstra, G., Jukema, J. W., Sun, F., & Gillen, D. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007307879 · Cited by 60
The gap between guidelines and practice in the treatment of type 2 diabetes
Jenssen, T. G., Tonstad, S., Claudi, T., Midthjell, K., & Cooper, J. G. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.12.025 · Cited by 60
Whaley, J. M., Tirmenstein, M. A., Reilly, Poucher, Saye, Parikh, & List (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22503 · Cited by 60
Montoya, P. A., Múñoz, Ó., Cardozo, D. M. G., García, O. M., Fernandez-Ávila, D. G., Casas, L. Á., Bohórquez, L. F., Toro, C. M. A., Carvajal, L., de Peña, D. R., et al. (2016) · Colombia medica · doi:10.25100/cm.v47i2.2207 · Cited by 60
The insulin resistance syndrome and coronary artery disease
Kendall, D. M., Sobel, B. E., Coulston, A. M., Peters, A. L., McLean, B. K., Peragallo‐Dittko, V., Buse, J. B., Fonseca, V. A., Hill, J. O., Nesto, R. W., et al. (2003) · Coronary Artery Disease · doi:10.1097/01.mca.0000076512.29238.2a · Cited by 61
Monnier, L., Colette, C., & Owens, D. R. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101225 · Cited by 61
Diabetic nephropathy: A twisted thread to unravel
Dagar, N., Das, P., Bisht, P., Taraphdar, A. K., Ravichandiran, V., & Arumugam, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119635 · Cited by 60
Screening for chronic kidney disease: which strategy?
Hallan, S. I., & Stevens, P. E. (2010) · Journal of Nephrology · doi:10.1093/joneph/23.2.147 · Cited by 59
Hohlfeld, T., Zimmermann, N., Weber, A.-A., Jessen, G., Weber, H., Schrör, K., Höltje, H. D., & Ebel, R. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02800.x · Cited by 59
Kumeda, Y., Inaba, M., Shoji, S., Ishimura, E., Inariba, H., Yabe, S., Okamura, M., & Nishizawà, Y. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03202.x · Cited by 59
Akalin, S., Berntorp, K. E., Ceriello, A., Das, A. K., Kilpatrick, E. S., Koblik, T., Munichoodappa, C., Pan, C., Rosenthall, W., Shestakova, M. V., et al. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02165.x · Cited by 59
Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus
STOLAR, M. W. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0471 · Cited by 60
Treatment of Cardiac Risk Factors Among Patients With Schizophrenia and Diabetes
Weiss, A. P., Henderson, D. C., Weilburg, J. B., GOFF, D. C., Meigs, J. B., Cagliero, E., & Grant, R. W. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.8.1145 · Cited by 59
von Scholten, B. J., Reinhard, H., Hansen, T. W., Schalkwijk, C. G., Stehouwer, C. D. A., Parving, H., Jacobsen, P. K., & Rossing, P. R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.11.005 · Cited by 59
Self-citationL-arginine, tetrahydrobiopterin, nitric oxide and diabetes
Hoang, H. H., Padgham, S., & Meininger, C. J. (2012) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32835ad1ef · Cited by 59
Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance
Dimova, R. B., Tankova, T. I., Guergueltcheva, V., Tournev, I., Chakarova, N. Y., Grozeva, G. G., & Dakovska, L. N. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.002 · Cited by 62
Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives
Rossing, P. R., Persson, F., & Frimodt‐Møller, M. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.007 · Cited by 62
Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients
Moțățăianu, A., Maier, S., Bajkó, Z., Voidăzan, S. T., Bălașa, R., & Stoian, A. (2018) · BMC Neurology · doi:10.1186/s12883-018-1125-1 · Cited by 62
MacLean, C. D., Littenberg, B., Gagnon, M., Reardon, M., Turner, P. D., & Jordan, C. (2004) · Clinical Trials · doi:10.1191/1740774504cn051oa · Cited by 59
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 60
Diversity of pathophysiology in type 2 diabetes shown by islet pathology
Mizukami, H., & Kudoh, K. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13679 · Cited by 61
Atmaca, A. A., Ketenci, A., Şahin, İ., Şengün, İ. Ş., Öner, R. İ., Tilki, H. E., Adaş, M., Soyleli, H., & Demir, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1380929 · Cited by 62
Cardiovascular safety profile of currently available diabetic drugs.
Azimova, K., Juan, Z. T. S., & Mukherjee, D. (2014) · PubMed Central · Cited by 58
Mattila, T., & de Boer, A. (2010) · Drugs · doi:10.2165/11585220-000000000-00000 · Cited by 59
The Conductor of the Autonomic Orchestra
Vinik, A. I. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00071 · Cited by 59
Diabetic cardiovascular autonomic neuropathy: clinical implications
Karayannis, G., Giamouzis, G., Cokkinos, D. V., Skoularigis, J. S., & Triposkiadis, F. K. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.53 · Cited by 59
Diabetic angiopathy and angiogenic defects
Xu, L., Kanasaki, K., Kitada, M., & Koya, D. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-13 · Cited by 58
Update on the Canadian Diabetes Association 2008 clinical practice guidelines.
Bhattacharyya, O. K., Estey, E. A., & CHENG, A. Y. Y. (2009) · PubMed Central · Cited by 58
Kitada, M., Ogura, Y., Monno, I., & Koya, D. (2018) · Nutrients · doi:10.3390/nu10050544 · Cited by 60
The Management of Diabetic Neuropathy in CKD
Pop‐Busui, R., Roberts, L., Pennathur, S., Kretzler, M., Brosius, F. C., & Feldman, E. L. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.10.050 · Cited by 58
Management of the metabolic syndrome.
Scheen, A. J. (2004) · PubMed · Cited by 58
Elkeles, R. S., Feher, M. D., Flather, M. D., Godsland, I. F., Nugara, F., Richmond, W., Rubens, M., & Wang, D. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01409.x · Cited by 58
Earle, K. A., Istepanian, R. S. H., Zitouni, K., Sungoor, A., & Tang, B. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0090 · Cited by 57
Kidney failure: aims for the next 10 years and barriers to success
Remuzzi, G., Benigni, A., Finkelstein, F. O., Grünfeld, J., Joly, D., Katz, I. J., Liu, Z.-H., Miyata, T., Perico, N., Rodríguez‐Iturbe, B., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60438-9 · Cited by 57
Blood pressure targets in adults with hypertension
Arguedas, J. A., Leiva, V., & Wright, J. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004349.pub3 · Cited by 59
The Role of Biofactors in Diabetic Microvascular Complications
Ziegler, D., Porta, M., Παπάνας, Ν., Moța, M., Jermendy, G., Beltramo, E., Mazzeo, A., Caccioppo, A., Striglia, E., Serhiyenko, V. A., et al. (2021) · Current Diabetes Reviews · doi:10.2174/1871527320666210825112240 · Cited by 58
Geng, T., Xu, W., Gao, H., Zhang, J., Zou, J., Wang, K., Li, J., Guo, L., Wang, G., Chen, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.041 · Cited by 57
Effect of systemic medications on onset and progression of diabetic retinopathy
Silva, P. S., Cavallerano, J. D., Sun, J. K., Aiello, L. M., & Aiello, L. P. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.122 · Cited by 57
Lü, B., Wen, J., Song, X., Dong, X., Yang, Y., Zhang, Z., Zhao, N. Q., Ye, H. Y., Mou, B., Chen, F. L., et al. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.06.024 · Cited by 57
Clinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 57
Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Imprialos, K. P., Boutari, C., Stavropoulos, K., Doumas, M. N., & Karagiannis, A. I. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314704 · Cited by 58
Rhee, E., Han, K., Ko, S., Ko, K. S., & Lee, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176615 · Cited by 57
Colagiuri, S., Matthews, D. R., Leiter, L. A., Chan, S. P., Sesti, G., & Marre, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.028 · Cited by 59
Type 2 diabetes mellitus: a cardiovascular perspective
Varughese, G. I., Tomson, J., & Lip, G. Y. H. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00571.x · Cited by 57
Roozendaal, B. W., & Krass, I. (2009) · Pharmacy World & Science · doi:10.1007/s11096-009-9312-1 · Cited by 58
Glycemic Control and Prevention of Microvascular and Macrovascular Disease in The Steno 2 Study
Vaag, A. A. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.89 · Cited by 57
Metabolic Disorders with Kidney Transplant
Cohen, E., Korah, M. M., Callender, G. G., Aguiar, R. B. D., & Haakinson, D. J. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09310819 · Cited by 56
Protein restriction for diabetic kidney disease
Jiang, S., Fang, J., & Li, W. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014906.pub2 · Cited by 56
Do angiotensin II receptor blockers increase the risk of myocardial infarction?
Verdecchia, P., Angeli, F., Gattobigio, R., & Reboldi, G. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi445 · Cited by 56
Fan, W., Song, Y., Inzucchi, S. E., Sperling, L. S., Cannon, C. P., Arnold, S. V., Kosiborod, M., & Wong, N. D. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13625 · Cited by 58
Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late
Javed, S., Hayat, T., Menon, L., Alam, U., & Malik, R. A. (2019) · Diabetic Medicine · doi:10.1111/dme.14194 · Cited by 61
Metabolic Syndrome and Cardiovascular Disease
Citrome, L. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105058375 · Cited by 56
The metabolic syndrome as a link between smoking and cardiovascular disease
Dzien, A., Dzien‐Bischinger, C., Hoppichler, F., & Lechleitner, M. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00324.x · Cited by 56
Messerli, F. H., Bakris, G. L., Ferrera, R. D., Houston, M. C., Petrella, R. J., Flack, J. M., Sun, W. Y., Lee, E., Neutel, J. M., & on behalf of the AVALON Investigators (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.05636.x · Cited by 56
Anselmino, M., Bartnik, M., Malmberg, K., Rydén, L., & on behalf of the Euro Heart Survey Investigators (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000199496.23838.83 · Cited by 56
Griffin, S. J., Rutten, G. E. H. M., Khunti, K., Witte, D. R., Lauritzen, T., Sharp, S. J., Dalsgaard, E.-M., Davies, M. J., Irving, G. J., Vos, R. C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30349-3 · Cited by 55
Update on the Management of Diabetic Neuropathy
Ang, L., Cowdin, N., Mizokami-Stout, K., & Pop-Busui, R. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0036 · Cited by 55
French, D., Wade, A. N., & Farmer, A. A. (2013) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.12.008 · Cited by 55
Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy
Smith, A. G. (2012) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2012.00390.x · Cited by 55
MacLean, C. D., Gagnon, M., CALLAS, P. W., & Littenberg, B. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1147-x · Cited by 56
Progression of chronic kidney disease: Can it be prevented or arrested?
Jaber, B. L., & Madias, N. E. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.032 · Cited by 55
Metadata
- Authors
- Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- Herlev Hospital (DK)
- Roskilde Sygehus (DK)
- Aarhus University (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-30
- Volume
- 348
- Issue
- 5
- Pages
- 383-393
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139634859
- Cited by
- 4,378
- References
- 26
- Citations by year
- 2026: 47 · 2025: 71 · 2024: 108 · 2023: 110 · 2022: 102 · 2021: 137 · 2020: 142 · 2019: 133 · 2018: 171 · 2017: 143 · 2016: 158 · 2015: 169 · 2014: 198 · 2013: 184 · 2012: 235
- FWCI
- 178.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, multifactorial intervention, microalbuminuria, tight glycemic control, hyperglycemia, hypertension, dyslipidemia, aspirin, myocardial infarction, stroke, kidney disease, retinopathy, autonomic neuropathy
- MeSH terms
- Amputation, Surgical, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Combined Modality Therapy, Diabetes Mellitus, Diabetes Mellitus, Type 2, Female, Humans, Hyperlipidemias, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Obesity, Risk Factors, Vitamins, Exercise, Smoking Cessation, Diet, Fat-Restricted, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
